In a previous study, we found that the CYP2D6 phenotype determined by 13 C-dextromethorphan breath test (DM-BT) might be used to predict tamoxifen treatment outcome in breast cancer patients in the adjuvant setting. However, large variation in the Delta-over-baseline (DOB) values was observed in the extensive metabolizer predicted phenotype group based on single point measures. In the present work we aimed to analyze the variability of phenotype results and determine reproducibility to further characterize the clinical utility of DM-BT by introducing multiple breath sampling instead of single breath sampling and by administration of a fixed dose of 13 C-DM. A total of 6 extensive metabolizers (EMs) patients by predicted phenotype with early breast cancer using tamoxifen in the adjuvant setting were phenotyped for CYP2D6 by the DM-BT on three separate days using a fixed 50 mg dose of DOB 50 values with a fixed dose of 50 mg 13 C-DM were 10.3-75.6% higher compared to predicted DOB 50 values when using a 0.5 mg kg -1 dose, suggesting higher metabolic rate with higher dosing in CYP2D6 EMs. The findings suggest that the analytical variation in DM-BT results is sufficiently low. Although multiple breath samples theoretically might predict endoxifen serum levels better than single-point breath test, for practical purposes as a point of care diagnostic test, a single breath sample collection might be preferable. Using a higher fixed dose of the substrate probe 13 C-DM should be considered in future validation studies.
IntroductIon
Stable isotope-labeled substrates can be used to provide rapid in vivo phenotype assessment of drug metabolizing enzymes. A few rapid, non-invasive, phenotype breath tests have been researched using [ 13 C]-pantoprazole [1] [2] [3] [4] [5] [6] , [ 13 C]-dextromethorphan [7] [8] [9] Tamoxifen is commonly used for the treatment of adjuvant breast cancer. Only one third of women with localized hormone receptor positive breast cancer benefit from adjuvant tamoxifen. This variable response to tamoxifen treatment might be at least partially explained by interindividual variability in tamoxifen biotransformation to active metabolites, of which endoxifen is the most critical in determining efficacy. CYP2D6 mediated metabolism is considered the main route of activation of tamoxifen into active endoxifen along with CYP3A4. In a recent study, endoxifen serum levels of >5.97 ng/mL have been associated with lower breast cancer recurrence rate [15] . However, variability in endoxifen levels is only explained for 23% by CYP2D6 genotype [16] suggesting that other extraneous factors might also play an important role in variability of endoxifen levels.
CYP2D6 phenotype includes both CYP2D6 genotype and interacting environmental factors or co-medications. Therefore, determination of CYP2D6 phenotype by a noninvasive single-point 13 C-dextromethorphan breath test (DM-BT) [17] might be of clinical use in prediction of serum endoxifen levels and thus tamoxifen treatment outcome. We have shown that this test is useful in distinguishing between patients with suggested therapeutic serum endoxifen levels and those with suggested subtherapeutic levels [8] . However, variability in endoxifen levels was explained for only 48.7% by CYP2D6 phenotype by single-point DM-BT. This might be explained by the fact that other enzymes than CYP2D6, such as CYP3A, might be involved in tamoxifen metabolism.
However, even a large interpatient variability in DM-BT results in the subgroup of patients with 13 C-dextromethorphan breath test Chapter 5 EM CYP2D6 genotype was observed, which could not be explained by co-medication (such as CYP2D6 inhibitors), since the usage was not allowed in the study. It is therefore hypothesized that variability in DM-BT results might partially be due to technical aspects of the DM-BT and therefore, further characterization of test performance is warranted. Several factors might contribute to the large interpatient variability in DM-BT results, including variability in dextromethorphan (the test probe) disposition and moderate test performance due to single-time-point breath sampling. This study focussed on the further characterization of the existing single-point DM-BT by introducing multiple breath sampling over time using a fixed dose of the probe substrate 13 C-DM versus the weight based dose in the previous study. We hypothesized that CYP2D6 phenotype by using DM-BT based on collection of multiple breath samples might help explain the variability in endoxifen levels compared to CYP2D6 phenotype using DM-BT based on single point breath sample.
Methods study design
This pharmacokinetic study was conducted in the Leiden University Medical Center, approved by the institutional review board of the study site and all patients provided written informed consent.
A total of 6 patients were recruited from the multicenter, prospective CYPTAM study (NTR1509). In this substudy, CYP2D6 genotype and CYP2D6 phenotype by DM-BT were determined. Women 18 years and older with early stage estrogen receptor positive breast cancer who were on adjuvant tamoxifen therapy at a daily dose of 20 mg for at least two months, were eligible. Exclusion criteria for this study were a poor metabolizer (PM) CYP2D6 predicted phenotype by means of the genotype, since DM-BT results were near zero, patients unwilling to fast overnight, to abstain from alcohol for at least 24 hours prior to the DM-BT, with known allergy to DM, with grade ≥3 
Analysis of

determination of serum levels of tamoxifen and metabolites
Ten mL of blood was collected on the first visit, centrifuged and stored at -20°C for serum analysis of tamoxifen and metabolites. Blood samples were taken up to 12 hours before the next dosage of tamoxifen (trough levels). Serum levels of tamoxifen and its metabolites 4-hydroxytamofen, N-desmethyltamoxifen and endoxifen were determined by liquid chromotography, coupled with tandem-mass-spectrometry (LC-MS) [18] .
dM-bt
Isotopically labeled CO 2 breath test have been investigated as minimally invasive procedures for estimating drug biotransformation activity [19] . CYP2D6 mediated O-demethylation of 13 C-DM leads to dextrorphan and the released methyl group is involved in the formation of 13 CO 2 that is released in expired breath over time [17] :
The concentration of 13 CO 2 and 12 CO 2 in the exhaled breath samples was measured by infrared spectrometry using a POCOne ® spectrophotometer (Otsuka Electronics Co. Ltd., Osaka, Japan). Trapezoidal AUC 0-4h (full AUC) was calculated from all measured DOB-timepoints (T=0-4h) using trapezoidal rule. Additionally time to which maximum DOB value (T DOBmax ) was reached was calculated.
Intraday analytical variation of DM-BT was determined in triplicate by analysis of three single breath samples on one single day ten times, and expressed as variation coefficient (VC=standard deviation (SD)/mean).
Interday analytical variation of DM-BT expressed as VC was determined by repetition of breath sample analysis of one single breath sample on day 0, 1, 2, 3, 4, 5, 10, 15, 20, and 30.
Results from DM-BT identified the CYP2D6 phenotype of participating subjects. From each patient and on each day, AUC DOB0-4h was calculated using the trapezoidal method. Intrapatient variation in T DOBmax , CYP2D6 phenotype expressed as VC of AUC DOB0-4h , were calculated for each patient (n=3 days). 
Analytical variation
Mean intraday analytical variation of DOB50 for three breath samples was 9.9% as shown in Table 5 .1a. Interday analytical VC was 11.7% (Table 5 .1b). There was no trend in decreasing DOB50 values over time, excluding the possibility of adsorption of 13 C to the aluminum wall of the breath bag, consistent with the finding by Mattison et al. [20] who had shown that the 13 CO 2 content in breath collection bags stored at room temperature is stable up to 210 days.
Intrapatient interday variability in cYP2d6 phenotype
Intrapatient interday variability in CYP2D6 phenotype determined by DM-BT was studied in respect to variation in time by which maximum DOB value was reached (T DOBmax min) and the AUC DOB0-4h (‰xh) ( Table 5 .2). Except for the large variation of T DOBmax in patient 5 (60-120 minutes),
TDOBmax was in the range of 30 to 60 minutes in the other patients. In patient 5 the T max was delayed which might be due to slower gastrointestinal absorption of C-DM-BT, 13 C-dextromethorphan breath test; DOB 50 , delta-over-baseline on t = 50 min; Min.,minimum; Max., maximum; SD, standard deviation; VC, variation coefficient. with AUCs DOB 0-2 h (‰xh) than AUCs DOB 0-4h (‰xh) since it more closely measures the first pass metabolism of the 13 C-DM following ingestion. C-DM-BT, 13 C-dextromethorphan breath test; DOB 50 , delta-over-baseline on t = 50 min; Min., Minimum;Max., maximum; SD, standard deviation; VC, variation coefficient.
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effect of probe dose on cYP2d6 activity
In our previous study [8] , we observed a non-linearity between gene activity score and DOB 50 in CYP2D6 IMs and EMs, with flattening of the curve in EMs, suggesting that CYP2D6 enzyme 
dIscussIon
This is the first pharmacokinetic study which investigated the analytical and patient related variability in clinical CYP2D6 phenotype by DM-BT. DM-BT was introduced as a rapid phenotyping assay for CYP2D6 activity, using single point determination of 13 CO 2 enrichment by infrared spectrometry (delta-over-baseline (DOB) value) in expired air breath samples [17] . In our previous study [8] , we have shown that in 65 breast cancer patients, assessment of the CYP2D6 phenotype by DM-BT might discriminate patients with suggested subtherapeutic (<5.97 ng/mL) and therapeutic (≥5.97 ng/mL) endoxifen levels [15] . However, in the large subset of patients with EM predicted phenotype, we observed a large interpatient variation in the CYP2D6 phenotype determined by DM-BT, which could not be explained by use of CYP2D6 inhibiting medication.
DM-BT measures a metabolic response to a dose of the administered 13 C-enriched DM substrate.
13
CO 2 is the biomarker, which is analyzed in breath samples. Intrapatient interday variation of the CYP2D6 phenotype was assessed for various DM-BT parameters. Except for the large variation of T DOBmax in patient 5 (60-120 minutes), T DOBmax was in the range of 30 to 60 minutes in the other patients, which is consistent with the expected time of peak plasma concentration (T max ) for dextrorphan [21] . Although all patients were fasting (for a minimum of 8 h), sober (for a minimum of 24h) and abstained from medication which might slow GI motility (for a minimum of 12h), differences in T DOBmax over days could be attributable to differences in GI motility, for which recently a circadian rhythm in the fasted state has been discovered [22] . Although an intrapatient interday variation in C DOBmax was observed, intrapatient interday variation in AUCs was considerable low (VC 3.3 to 15.5%), stressing the unique and consistent metabolism of the substrate in each patient. To date, no circadian rhythm in CYP2D6 first-pass metabolism has been observed. In contrast, interpatient difference in AUCs were 22%
higher (Table 5. 2), consistent with the high variability of DM-BT DOB 50 results we observed in patients with CYP2D6 EM predicted phenotype in our previous study [8] and stressing the heterogeneity of CYP2D6 phenotype among genetically identical subjects.
DOB 50 values in this fixed 50 mg DM dose study were higher compared to predicted DOB 50 values
(by linear extrapolation of data from the previous [8] weight-adjusted dose study to a 50 mg fictive dose of 13 C-DM (Table 5. 3), suggesting higher metabolic rate with higher dosing.
This finding is consistent with the fact that CYP2D6 mediated DM metabolism follows first-order pharmacokinetics. This data confirms our hypothesis that EM patients with higher CYP2D6 enzyme activity may not have received adequate dextromethorphan-
C to truly reflect their enzyme activity. A mean C max of 14 uM dextrorphan (DXO) was observed [23] after administration of 60 mg DM, far below the DXO Michaelis constant Km (which is the substrate concentration at which the reaction rate is half of the maximum metabolic speed (V max )) of 1220 uM [24] . Therefore, with the 50 mg DM dose in our study, CYP2D6 was expected not to be saturated in EMs and the nonlinearity between genotype and phenotype we observed between subjects with IM and EM predicted phenotype in our previous study could not be explained by enzyme saturation. We have shown that DM-BT was able to predict suggested therapeutic endoxifen levels of ≥5.97 ng/mL with a positive predictive value of 100% and a negative predictive value of 90% [8] . However, we observed a large interindividual variation in endoxifen levels in the EM group of patients. Patient numbers in this study are however too low to correlate CYP2D6 phenotype with endoxifen levels in respect to single or multiple breath sampling. Further studies should investigate whether limited multiple breath sampling would be able to improve prediction of endoxifen levels compared to single breath sampling in all three genotype subgroups (PM, IM, EMs). With an already 100% PPV and 90% NPV with single breath sampling, further improvement by introducing a time consuming limited multiple breath sampling might not improve clinical decision making.
In summary, with our study, we further characterized the DM-BT in respect to analytical variation, an alternative fixed dose regimen and the introduction of multiple breath sampling. Our findings suggest that the analytical variation in DM-BT results is sufficiently low. With a fixed dose of 50 mg 13 C-DM compared to using a 0.5 mg/kg dose higher DOB were observed, suggesting higher metabolic rate with higher dosing in CYP2D6 EMs. The optimal dosing of the 13 C-DM probe should be part of further research. Due to the low number of patients in the study no conclusions can be drawn regarding the potential superior correlation between CYP2D6 phenotype and endoxifen serum levels by introducing limited breath sampling compared to a slngle breath test. However, from practical considerations, a single breath test might be preferable and adequate. Further research would be necessary to determine if limited multiple breath sampling will influence the decision to choose between tamoxifen (for patients with predicted normal therapeutic endoxifen level) and an aromatase inhibitor (for patients with predicted subtherapeutic endoxifen level).
Our results do not support any change to the (weight-based) dose regimen and single-point sampling strategy of the DM-BT at this time.
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